Rockville, MD, Jan. 20, 2025 (GLOBE NEWSWIRE) -- According to Fact.MR, a market research and competitive intelligence provider, the global RNA transcriptome profiling test market is estimated to reach a valuation of US$ 9,652.2 million in 2024 and is expected to grow at a CAGR of 14.5% during the forecast period of (2024 to 2034).
The investments in biotechnology and genomics have been increasing, thus significantly driving the RNA transcriptome profiling test market for detection and understanding chronic diseases. In a situation where chronic illnesses like cancer, cardiovascular diseases, and neurodegenerative disorders present growing healthcare challenges, there is an increased need for advanced diagnostic methods offering deep insights into disease mechanisms. RNA transcriptome profiling tests meet this demand through comprehensive analysis of RNA expressions to show the molecular alterations associated with chronic conditions.
Governments and private entities around the world are increasing their investments in biotechnology to facilitate precision medicine and research in genomics. For example, there is the U.S. National Institutes of Health's investment in transcriptomics, which works toward improving diagnosis and therapy in cancer and other rare chronic diseases. Similarly, countries like India and China are investing in heavy biotechnology infrastructure to advance genomic studies, which include transcriptomics applications for chronic disease management.
Besides, the introduction of high-throughput sequencing technologies has improved access to RNA transcriptome profiling and increased its adoption into clinical and research settings. This growing focus on genomic insights is enhancing chronic disease diagnosis and allowing the development of targeted therapies, thus transforming patient care around the world.
For More Insights into the Market, Request a Sample of this Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=3113
Key Takeaways from Market Study:
- The global RNA transcriptome profiling test market is projected to grow at 14.5% CAGR and reach US$ 37,383.8 million by 2034
- The market created an absolute $ opportunity of US$ 27,731.5 million growing at a CAGR of 14.5% between 2024 to 2034
- North America is a prominent region that is estimated to hold a market share of 38.0% in 2034
- Predominating market players include Agilent Technologies, Inc., F. Hoffmann-La Roche AG, Illumina, Inc., Thermo Fisher Scientific, Inc., QIAGEN N.V., Bio-Rad Laboratories, Inc., Pacific Biosciences of California, Inc., Eurofins Scientific, Merck KGaA, Promega Corporation, 10x Genomics, Twist Bioscience, Bruker Spatial Biology, and Cepheid among others.
- High throughput method type is holding highest share of 75.3% in 2024 and is expected to reach at the value of US$ 2,785.5 million in 2034.
- North America and Western Europe are expected to create an absolute $ opportunity of US$ 15,661.0 million collectively.
“RNA transcriptome profiling tests are widely used in cancer research due to its ability to identify tumor-specific RNA signatures, enabling precise biomarker discovery and the development of personalized treatment strategies” says a Fact.MR analyst.
Leading Players Driving Innovation in the RNA Transcriptome Profiling Test Market:
Agilent Technologies, Inc.; F. Hoffmann-La Roche AG; Illumina, Inc.; Thermo Fisher Scientific, Inc.; QIAGEN N.V.; Bio-Rad Laboratories, Inc.; Pacific Biosciences of California, Inc.; Eurofins Scientific; Merck KGaA; Promega Corporation; 10x Genomics; Twist Bioscience; Bruker Spatial Biology; Cepheid
Tumor-specific RNA signature identifications have made RNA transcriptome profiling tests important in cancer research. These tests offer comprehensive gene expression profiling analyses that can help distinguish normal from malignant tissues. Such would be important in the accurate identification of biomarkers that are usually necessary in the early diagnosis and monitoring of disease conditions for which predictions about the response of the patients to specific therapies is done.
These insights into RNA profiling also drive personalized treatment strategies-one of the cornerstones of precision medicine. Analysis of tumor-specific RNA expression patterns allows researchers to identify molecular targets for therapies tailored for individual patients. This is notably important in heterogeneous cancers, where genetic variations demand highly personalized interventions.
RNA Transcriptome Profiling Test Industry News:
- Illumina, Inc. will debut its MiSeq i100 Series of sequencing devices in October 2024, offering exceptional benchtop speed and simplicity to push the boundaries of next-generation sequencing (NGS) in labs.
- In September 2024, the company introduced 100 new assays for its QIAcuity digital PCR (dPCR) platform, which would be used in cancer research, inherited genetic disorders, infectious disease surveillance, and food and environmental monitoring.
- In May 2023, Pfizer and Thermo Fisher Scientific Inc. signed a collaborative agreement to improve local access to NGS-based testing for patients with lung and breast cancer in more than 30 countries across Latin America, Africa, the Middle East, and Asia.
- Agilent Technologies Inc. and Theragen Bio of South Korea formed a partnership in April 2023 to leverage both companies' complementary strengths in cancer genomic profiling design, engineering knowledge, and software experience to drive localised analysis capabilities, thereby speeding up treatment decisions.
Get Customization on this Report for Specific Research Solutions:
https://www.factmr.com/connectus/sample?flag=S&rep_id=3113
More Valuable Insights on Offer:
Fact.MR, in its new offering, presents an unbiased analysis of the global RNA transcriptome profiling test market, presenting historical data for 2019 to 2023 and forecast statistics for 2024 to 2034.
The study reveals essential insights on the basis of the component type (consumables- reagents, kits, and dyes; instruments- RT PCR, microarray, sanger sequencing platform, and RNA sequencing platform; software; and services), method type (conventional methods & high throughput methods), application (cancer research, complex disease biomarker identification, agrigenomics, RNA-based drug response biomarker discovery, and others), and end user (hospital based laboratories, diagnostic centers, academic and research institutes, contract research organizations (CROs), and others) across major regions of the world (North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia & Pacific, and Middle East & Africa).
Check out More Related Studies Published by Fact.MR:
The global DNA and RNA sample preparation market is estimated to be worth US$ 1,967.5 million in 2024. The market is expected to register a CAGR of 5.7% from 2024 to 2034. The growth of the market over the forecast period is set to see the market size expand, reaching a projected value of US$ 3,413.8 million in 2034.
The human papillomavirus (HPV) testing market size is estimated to be valued at US$ 1,214.0 million in 2024. The market is expected to expand at a CAGR of 10.3% through 2034. Anticipated growth is set to propel the market to an impressive size of US$ 3,236.3 million by 2034.
The global ovulation test market stands at US$ 2.51 billion in 2023. Worldwide demand for fertility monitors is predicted to increase at a CAGR of 4.1% and reach a market value of US$ 3.76 billion by the end of 2033.
The laboratory developed test market size is anticipated to be worth US$ 8,698.6 million in 2024, and is projected to expand at a CAGR of 6.5%, resulting in a valuation of US$ 16,404.2 million by 2034.
Newly-released efficacy testing market analysis report by Fact.MR reveals that global sales in 2022 were held at US$ 320 million. With 6.4% projected growth from 2023 to 2033.
About Us:
Fact.MR is a distinguished market research company renowned for its comprehensive market reports and invaluable business insights. As a prominent player in business intelligence, we deliver deep analysis, uncovering market trends, growth paths, and competitive landscapes. Renowned for its commitment to accuracy and reliability, we empower businesses with crucial data and strategic recommendations, facilitating informed decision-making and enhancing market positioning.
With its unwavering dedication to providing reliable market intelligence, FACT.MR continues to assist companies in navigating dynamic market challenges with confidence and achieving long-term success. With a global presence and a team of experienced analysts, FACT.MR ensures its clients receive actionable insights to capitalize on emerging opportunities and stay competitive.
Contact:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Sales Team: sales@factmr.com
Follow Us: LinkedIn | Twitter | Blog
